Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.25 (
MEKK1
)
1,856
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
TAK1
(transforming growth factor-beta-activated kinase-1), a
MAP3K
with considerable sequence similarity to Raf-1 and
MEKK
-1, has been identified as a transforming growth factor-beta/bone morphogenetic protein (BMP)-activated cytosolic component of the MAPK pathways. In this investigation, the molecular interactions between
TAK1
and Smad proteins were characterized as well as their influence on BMP-mediated mesenchymal cell differentiation along the osteogenic/chondrogenic pathway. In co-immunoprecipitations we found an interaction of
TAK1
with all Smads tested, R-Smads Smads1-5, the co-Smad Smad4, and the inhibitory Smads (I-Smad6 and I-Smad7). Smad interaction with
TAK1
takes place through their MH2 domain. This interaction is dependent on the presence of an active kinase domain in
TAK1
.
TAK1
dramatically interferes with R-Smad transactivation in reporter assays and affects subcellular distribution of Smad proteins. Activated
TAK1
also interferes with BMP-dependent osteogenic development in murine mesenchymal progenitor cells (C3H10T 1/2). A potential
TAK1
-mediated apoptosis process could be excluded for these cells. Both synergistic and interfering influences of
TAK1
on BMP-mediated Smad-signaling have been reported previously. We suggest that
TAK1
is a factor that is involved in the fine-tuning of BMP effects during osteogenic development.
...
PMID:Transforming growth factor-beta-activated kinase-1 (TAK1), a MAP3K, interacts with Smad proteins and interferes with osteogenesis in murine mesenchymal progenitors. 1591 26
Kinase suppressor of ras (KSR) and
MEKK3
(
MAP kinase kinase kinase
) are integral members of the MAP kinase pathway. We have recently identified a new isoform of the KSR family named human kinase suppressor of ras-2 (hKSR-2), and demonstrated that hKSR-2 negatively regulates Cot, a
MAP3K
family member which is important in inflammation and oncogenesis [P.L. Channavajhala, L. Wu, J.W. Cuozzo, J.P. Hall, W. Liu, L.L. Lin, Y. Zhang, J. Biol. Chem. 278 (2003) 47089-47097]. In this report, we provide evidence that hKSR-2 also regulates the activity of
MEKK3
(another
MAP3K
family member) in HEK-293T cells. We demonstrate that hKSR-2 is a negative regulator of
MEKK3
-mediated activation of MAP kinase (specifically ERK and JNK) and NF-kappaB pathways, and concurrently inhibits
MEKK3
-mediated interleukin-8 production. We find that while hKSR-2 blocks
MEKK3
activation, it has little to no effect on other members of the
MAP3K
family, including MEKK4,
TAK1
, and Ras-Raf, suggesting that its effects are selective.
...
PMID:hKSR-2 inhibits MEKK3-activated MAP kinase and NF-kappaB pathways in inflammation. 1603 90
Infection of Drosophila by Gram-negative bacteria triggers a signal transduction pathway (the IMD pathway) culminating in the expression of genes encoding antimicrobial peptides. A key component in this pathway is a Drosophila IkappaB kinase (DmIKK) complex, which stimulates the cleavage and activation of the NF-kappaB transcription factor Relish. Activation of the DmIKK complex requires the
MAP3K
dTAK1, but the mechanism of dTAK1 activation is not understood. In human cells, the activation of
TAK1
and IKK requires the human ubiquitin-conjugating enzymes Ubc13 and UEV1a. Here we demonstrate that the Drosophila homologs of Ubc13 and UEV1a are similarly required for the activation of dTAK1 and the DmIKK complex. Surprisingly, we find that the Drosophila caspase DREDD and its partner dFADD are required for the activation of DmIKK and JNK, in addition to their role in Relish cleavage. These studies reveal an evolutionarily conserved role of ubiquitination in IKK activation, and provide new insights into the hierarchy of signaling components in the Drosophila antibacterial immunity pathway.
...
PMID:The role of ubiquitination in Drosophila innate immunity. 1608 24
Transforming growth factor-beta1 (TGF-beta1) alters myocardial gene expression, resulting in myocyte hypertrophy, through activation of TGF-beta-activated kinase (
TAK1
), a member of the
mitogen-activated protein kinase kinase kinase
(
MAPKKK
) family. We hypothesized that the TGF-beta1-
TAK1
-p38 MAPK pathway might be activated during ventricular remodeling after myocardial infarction (MI). One, 3, 7, and 14 days after ligation of the left anterior descending coronary artery, noninfarcted left ventricular tissue samples were obtained. Protein levels as well as mRNA levels of the signaling pathway, TGF-beta1, TGF-beta-receptors, and
TAK1
increased in the noninfarcted myocardium in MI rats compared with sham-operated animals. Phosphorylation of MAPKK 3/6 (MKK3/6) and p38 MAPK, the downstream targets of
TAK1
, was also increased in the noninfarcted region. Moreover, an in vitro kinase assay revealed that the activated
TAK1
in the noninfarcted myocardium was capable of activating recombinant MKK3/6, suggesting a causative role of
TAK1
in the remodeling process. The activation of the TGF-beta1-
TAK1
-p38 MAPK pathway paralleled the transcriptional upregulation of cardiac markers for ventricular hypertrophy, beta-myosin heavy chain and atrial natriuretic peptide.
TAK1
was mainly localized to cardiomyocytes, whereas TGF-beta1 receptors were observed in vascular smooth muscle cells and fibroblasts as well as cardiomyocytes. Thus the TGF-beta1-
TAK1
-MKK3/6-p38 MAPK pathway in the cardiomyocytes of noninfarcted spared myocardium is activated after acute MI and may play an important role in ventricular hypertrophy and post-MI remodeling in rats.
...
PMID:Activation of TGF-beta1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. 1618 34
Receptor-interacting protein (RIP) plays a critical role in tumor necrosis factor-alpha (TNF-alpha)-induced IkappaB kinase (IKK) activation and subsequent activation of transcription factor NF-kappaB. However, the molecular mechanism by which RIP mediates TNF-alpha-induced NF-kappaB activation is not completely defined. In this study, we have found that
TAK1
is recruited to the TNF-alpha receptor complex in a RIP-dependent manner following the stimulation of TNF-alpha receptor 1 (TNF-R1). Moreover, a forced recruitment of
TAK1
to TNF-R1 in the absence of RIP is sufficient to mediate TNF-alpha-induced NF-kappaB activation, indicating that the major function of RIP is to recruit its downstream kinases to the TNF-R1 complex. Interestingly, we also find that
TAK1
and
MEKK3
form a functional complex, in which
TAK1
regulates autophosphorylation of
MEKK3
. The
TAK1
-mediated regulation of
MEKK3
phosphorylation is dependent on the kinase activity of
TAK1
. Although
TAK1
-
MEKK3
interaction is not affected by overexpressed TAB1, TAB1 is required for
TAK1
activation and subsequent
MEKK3
phosphorylation. Together, we conclude that
TAK1
is recruited to the TNF-R1 complex via RIP and likely cooperates with
MEKK3
to activate NF-kappaB in TNF-alpha signaling.
...
PMID:TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation. 1626 Jul 83
Transforming growth factor-beta (TGF-beta)-activated kinase 1 (
TAK1
) is a member of the
MAPKKK
family of protein kinases, and is involved in intracellular signalling pathways stimulated by transforming growth factor beta, interleukin-1 and tumour necrosis factor-alpha.
TAK1
is known to rely upon an additional protein, TAK1-binding protein 1 (TAB1), for complete activation. However, the molecular basis for this activation has yet to be elucidated. We have solved the crystal structure of a novel
TAK1
chimeric protein and these data give insight into how
TAK1
is activated by TAB1. Our results reveal a novel binding pocket on the
TAK1
kinase domain whose shape complements that of a unique alpha-helix in the
TAK1
binding domain of TAB1, providing the basis for an intimate hydrophobic association between the protein activator and its target.
...
PMID:Structural basis for the interaction of TAK1 kinase with its activating protein TAB1. 1628 17
We have recently established a TNF-alpha-promoted metastasis model, in which the ability to metastasize to the lung was enhanced by stimulation of cultured colon 26 cells with TNF-alpha before intravenous inoculation. To investigate intracellular events in metastatic cascades of TNF-alpha-treated cancer cells, we have focused on the stress signaling pathways to c-Jun N-terminal kinase (JNK) and p38. Treatment with a specific inhibitor, SP600125 or SB203580, in vitro suppressed TNF-alpha-induced migration and pulmonary metastasis. Activation of endogenous
TAK1
, a mitogen-activated protein kinase (
MAP3K
) regulating the JNK and p38 MAPK pathways, was induced rapidly by TNF-alpha, and co-transfection of
TAK1
with its activator protein TAB1 stimulated activation of JNK and p38 MAPKs, which led to activation of the transcription factor AP-1. The activation of stress signaling pathways by
TAK1
resulted in enhanced migration to fibronectin in vitro and metastasis to the lung in vivo without affecting cell proliferation in vitro and tumor growth in vivo. Moreover, knockdown of endogenous
TAK1
using small interfering RNA (siRNA) suppressed the TNF-alpha-induced JNK/p38 activation, migration and pulmonary metastasis. These results indicate that
TAK1
-mediated stress signaling pathways in cancer cells are essential for TNF-alpha-promoted metastasis to the lung.
...
PMID:TAK1-mediated stress signaling pathways are essential for TNF-alpha-promoted pulmonary metastasis of murine colon cancer cells. 1638 69
Epstein-Barr virus latent membrane protein 1 (LMP1) activates NF-kappaB and c-Jun N-terminal kinase (JNK), which is essential for LMP1 oncogenic activity. Genetic analysis has revealed that tumor necrosis factor receptor-associated factor 6 (TRAF6) is an indispensable intermediate of LMP1 signaling leading to activation of both NF-kappaB and JNK. However, the mechanism by which LMP1 engages TRAF6 for activation of NF-kappaB and JNK is not well understood. Here we demonstrate that
TAK1
mitogen-activated protein kinase kinase kinase
and TAK1-binding protein 2 (TAB2), together with TRAF6, are recruited to LMP1 through its N-terminal transmembrane region. The C-terminal cytoplasmic region of LMP1 facilitates the assembly of this complex and enhances activation of JNK. In contrast, IkappaB kinase gamma is recruited through the C-terminal cytoplasmic region and this is essential for activation of NF-kappaB. Furthermore, we found that ablation of
TAK1
resulted in the loss of LMP1-induced activation of JNK but not of NF-kappaB. These results suggest that an LMP1-associated complex containing TRAF6, TAB2, and
TAK1
plays an essential role in the activation of JNK. However,
TAK1
is not an exclusive intermediate for NF-kappaB activation in LMP1 signaling.
...
PMID:TAK1 is a component of the Epstein-Barr virus LMP1 complex and is essential for activation of JNK but not of NF-kappaB. 1644 57
IL-1 plays a major role in inflammation and autoimmunity through activation of nuclear factor kappa B (NFkappaB) and MAPKs. Although a great deal is known about the mechanism of activation of NFkappaB and MAPKs by IL-1, much less is known about the down-regulation of this pathway. Suppressor of cytokine signaling (SOCS)-3 was shown to inhibit IL-1-induced transcription and activation of NFkappaB and the MAPKs JNK and p38, but the mechanism is unknown. We show here that SOCS-3 inhibits NFkappaB-dependent transcription induced by overexpression of the upstream IL-1 signaling molecules MyD88, IL-1R-activated kinase 1, TNF receptor-associated factor (TRAF)6, and TGFbeta-activated kinase (TAK)1, but not when the
MAP3K
MAPK/ERK kinase kinase-1 is used instead of
TAK1
, indicating that the target for SOCS-3 is the TRAF6/
TAK1
signaling complex. By coimmunoprecipitation, it was shown that SOCS-3 inhibited the association between TRAF6 and
TAK1
and that SOCS-3 coimmunoprecipitated with
TAK1
and TRAF6. Furthermore, SOCS-3 inhibited the IL-1-induced catalytic activity of
TAK1
. Because ubiquitination of TRAF6 is required for activation of
TAK1
, we analyzed the role of SOCS-3 on TRAF6 ubiquitination and found that SOCS-3 inhibited ubiquitin modification of TRAF6. These results indicate that SOCS-3 inhibits IL-1 signal transduction by inhibiting ubiquitination of TRAF6, thus preventing association and activation of
TAK1
.
...
PMID:Suppressor of cytokine Signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. 1654 9
TLR8-mediated NF-kappaB and IRF7 activation are abolished in human IRAK-deficient 293 cells and IRAK4-deficient fibroblast cells. Both wild-type and kinase-inactive mutants of IRAK and IRAK4, respectively, restored TLR8-mediated NF-kappaB and IRF7 activation in the IRAK- and IRAK4-deficient cells, indicating that the kinase activity of IRAK and IRAK4 is probably redundant for TLR8-mediated signaling. We recently found that TLR8 mediates a unique NF-kappaB activation pathway in human 293 cells and mouse embryonic fibroblasts, accompanied only by IkappaBalpha phosphorylation and not IkappaBalpha degradation, whereas interleukin (IL)-1 stimulation causes both IkappaBalpha phosphorylation and degradation. The intermediate signaling events mediated by IL-1 (including IRAK modifications and degradation and
TAK1
activation) were not detected in cells stimulated by TLR8 ligands. TLR8 ligands trigger similar levels of IkappaBalpha phosphorylation and NF-kappaB and JNK activation in
TAK1
(-/-) mouse embryo fibroblasts (MEFs) as compared with wild-type MEFs, whereas lack of
TAK1
results in reduced IL-1-mediated NF-kappaB activation and abolished IL-1-induced JNK activation. The above results indicate that although TLR8-mediated NF-kappaB and JNK activation are IRAK-dependent, they do not require IRAK modification and are
TAK1
-independent. On the other hand, TLR8-mediated IkappaBalpha phosphorylation, NF-kappaB, and JNK activation are completely abolished in
MEKK3
(-/-) MEFs, whereas IL-1-mediated signaling was only moderately reduced in these deficient MEFs as compared with wild-type cells. The differences between IL-1R- and TLR8-mediated NF-kappaB activation are also reflected at the level of IkappaB kinase (IKK) complex. TLR8 ligands induced IKKgamma phosphorylation, whereas IKKalpha/beta phosphorylation and IKKgamma ubiquitination that can be induced by IL-1 were not detected in cells treated with TLR8 ligands. We postulate that TLR8-mediated
MEKK3
-dependent IKKgamma phosphorylation might play an important role in the activation of IKK complex, leading to IkappaBalpha phosphorylation.
...
PMID:TLR8-mediated NF-kappaB and JNK activation are TAK1-independent and MEKK3-dependent. 1673 60
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>